

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**  
**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: April 27, 2020  
(Date of earliest event reported)

**ENTASIS THERAPEUTICS HOLDINGS INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38670**  
(Commission  
File Number)

**82-4592913**  
(I.R.S. Employer  
Identification No.)

**35 Gatehouse Drive**  
**Waltham, MA 02451**  
**(781) 810-0120**  
(Principal Executive Office)

**Telephone Number: (781) 810-0120**

**Not Applicable**  
Former name or former address, if changed since last report

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	ETTX	The Nasdaq Stock Market, LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 27, 2020, Nicholas Galakatos, Ph.D., a member of the Board of Directors (the “Board”) of Entasis Therapeutics Holdings Inc. (the “Company”), provided notice to the Company of his intent to resign from the Board effective May 1, 2020, to pursue further his increased responsibilities with The Blackstone Group Inc. Dr. Galakatos' resignation was not the result of any disagreement between Dr. Galakatos and the Company with respect to any matter relating to the Company's operations, policies or practices.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENTASIS THERAPEUTICS HOLDINGS INC.**

By: /s/ Elizabeth M. Keiley  
General Counsel

Dated: April 29, 2020